US9232885B2 - Method and device for detecting tumorous tissue in the gastrointestinal tract with the aid of an endocapsule - Google Patents

Method and device for detecting tumorous tissue in the gastrointestinal tract with the aid of an endocapsule Download PDF

Info

Publication number
US9232885B2
US9232885B2 US13/805,205 US201113805205A US9232885B2 US 9232885 B2 US9232885 B2 US 9232885B2 US 201113805205 A US201113805205 A US 201113805205A US 9232885 B2 US9232885 B2 US 9232885B2
Authority
US
United States
Prior art keywords
cell tissue
endocapsule
electromagnetic radiation
intensity
detector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US13/805,205
Other languages
English (en)
Other versions
US20130096438A1 (en
Inventor
Jens Fehre
Ralf Nanke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Siemens Healthcare GmbH
Original Assignee
Siemens AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens AG filed Critical Siemens AG
Assigned to SIEMENS AKTIENGESELLSCHAFT reassignment SIEMENS AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FEHRE, JENS, NANKE, RALFE
Publication of US20130096438A1 publication Critical patent/US20130096438A1/en
Application granted granted Critical
Publication of US9232885B2 publication Critical patent/US9232885B2/en
Assigned to SIEMENS HEALTHCARE GMBH reassignment SIEMENS HEALTHCARE GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIEMENS AKTIENGESELLSCHAFT
Assigned to FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. reassignment FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Gerich, Carola, Schreiber, Jürgen, Opitz, Jörg
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
    • A61B1/043—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances for fluorescence imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
    • A61B1/041—Capsule endoscopes for imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4205—Evaluating swallowing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G06K9/00147—
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698—Matching; Classification
    • G06K2209/053—
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V2201/00—Indexing scheme relating to image or video recognition or understanding
    • G06V2201/03—Recognition of patterns in medical or anatomical images
    • G06V2201/032—Recognition of patterns in medical or anatomical images of protuberances, polyps nodules, etc.

Definitions

  • the invention concerns a method to detect tumorous cell tissue in the gastrointestinal tract with the use of an endocapsule.
  • tissue samples are extracted and examined for the presence of a carcinoma.
  • a number of biopsies are frequently required.
  • a procedure known as auto-fluorescence endoscopy is used in which the fluorescence of substances inherent to the body is utilized, which substances occur in an increased concentration in malignant tissue due to increased metabolic activity.
  • An additional possibility for biopsy control is the application of endomicroscopy, i.e. an examination with the aid of a microscope integrated into an endoscope, wherein a contrast agent must be administered to the patient to stain the tissue.
  • endomicroscopy i.e. an examination with the aid of a microscope integrated into an endoscope, wherein a contrast agent must be administered to the patient to stain the tissue.
  • biopsies continue to be necessary in both cases.
  • the extracted tissue samples are histologically examined in a laboratory. For example, slices are produced from the deep-frozen tell tissue samples, which slices are then assessed by the pathologist. A high time cost is necessary for this since not only the sample preparation, but rather also the documentation and the transport require time. Wait times also cannot be avoided. The results are often only present a few days later, which leads to a large psychological stress for the respective patient.
  • Tumorous cell tissue is thereby made light-sensitive with suitable chemical substances, and fluorescence at the cells prepared in such a manner is excited upon exposure with light.
  • the light for excitation has a different color than the fluorescence light.
  • the substances that are used are strongly phototoxic and can cause necrosis at the correspondingly treated tissue. This can also be utilized for a therapy against carcinomatous tumors, but the knowledge of the positions and the propagation of tumorous cell tissue is required.
  • a technique known as 5-ALA induced detection in which 5-aminolevulinic acid is injected, or methods that are commercially known as Hexvix and TOOKAD and in which other photoactive substances are used, are used to detect tumorous cell tissue.
  • a method for a laser-induced fluorescence of tissue is moreover known from DE 689 25 586 T2, in which method it should be possible to conclude the respective cell tissue type via a fluorescence excitation and the detection of specific characteristic wavelengths in the detected wavelength spectrum of the fluorescence light.
  • An object of the invention is to achieve a detection of tumorous cell tissue in the gastrointestinal tract of a subject in the course of a capsule endoscopy in a shorter amount of time, and with sufficient finding certainty.
  • a radiation source present in an endocapsule locally defined electromagnetic radiation is emitted toward the cell tissue of the gastrointestinal tract that is to be examined (for example the stomach mucosa), and after a deactivation of the radiation source at the time t 0 , the decay response of the inherent fluorescence intensity of the cell tissue that is excited by the electromagnetic radiation is detected with temporal and spatial resolution.
  • the detection of the inherent fluorescence intensity takes place with one or more known sample rate(s) and is implemented for at least one wavelength.
  • the sample rate is preferably kept constant during the detection.
  • the difference autocorrelation function C(t) of the intensity decay response is determined according to Equations (1) and (2), under consideration of the respective known sample rate(s).
  • I(t ⁇ ) is the excited fluorescence light after an infinitely long relaxation that is very small.
  • the relaxation function R(t) results from the correlation function of the fluorescence fluctuations, wherein ⁇ > t represents the temporal mean.
  • the exponent H or the fractal dimension of the stochastic intensity fluctuations D F that can be calculated from this, is a characteristic value for the assessment.
  • D F 2 ⁇ H results and can be used to differentiate healthy and tumorous cell tissue.
  • the exponent H can be determined via linear regression.
  • the value D F can be used for a classification with regard to a tumor affliction of the respective exposed cell tissue.
  • a comparison with a tumor-specific threshold can be implemented for the classification.
  • a specification of a probability of a presence of a tumor can also take place in the classification.
  • the fractal dimension D F is calculated for the respective exposed cell tissue and the value of the determined fractal dimension D F can then be compared with a tumor-specific threshold. Upon exceeding the threshold, the exposed cell tissue of the cell tissue sample is classified as tumorous. Given a shortfall of this threshold, the cell tissue is healthy.
  • the threshold is a numerical value between 1 and 2.
  • An exposure, detection and calculation of the fractal dimension D F can thus be implemented at the examined cell tissue in vivo in order to localize healthy tissue and possible tumorous cell tissue.
  • a finding can take place at different positions in that the endocapsule is moved, guided by magnets, to the respective positions.
  • an endocapsule includes a magnet system which interacts with an external magnetic field, for example as described in DE 10142253 C1.
  • Electromagnetic radiation in the wavelength range between 200 nm and 650 nm are particularly suitable here.
  • Laser light sources can be used as a radiation source.
  • Electromagnetic radiation with a wavelength of 337 nm has proven to be advantageous for the excitation of the inherent fluorescence.
  • At least 30 wavelengths from the selected wavelength interval should be considered for the mean calculation.
  • the difference of the spacings of the wavelengths from this wavelength interval that are thereby considered should be respectively of equal size.
  • the detection can thus be implemented within a wavelength interval of 421 nm ⁇ 15 nm.
  • the detection can be implemented with a spectrometer at a sample rate ⁇ 1000 ps, preferably ⁇ 100 ps, particularly preferably at approximately 50 ps.
  • Examinations of cell tissue can be implemented at multiple positions. However, a respective identical exposure of the selected positions of the cell tissue should thereby be maintained. A respective identically large area should thus be exposed with the same respective energy. For this purpose, the spacing of one or more optical fibers from the surface of the cell tissue that is to be exposed should be constant. For an evaluation and possible consideration in an immediately following operative procedure on a patient (or an operative procedure that is to be implemented later) in which the examination has been implemented in vivo, the knowledge of the respective position at the cell tissue is thus to be detected and documented so that it can be reproduced.
  • electromagnetic radiation can, for example, be directed—through multiple, correspondingly arranged optical fibers—toward cell tissue or the cell tissue sample at various locations to excite the inherent fluorescence, and after the deactivation of the radiation source the intensity I(t) of the electromagnetic radiation emitted from the cell tissue as a result of the inherent fluorescence of the cell tissue are then directed via optical fibers to a detector.
  • an examination can be implemented promptly and directly in an operating room.
  • the invention offers a good basis for decision as to where and how much cell tissue should be operatively removed.
  • a device that includes an endocapsule for implementation of the method according to the invention is designed so that living cell tissue, defined locally, is charged with electromagnetic radiation emitted from a radiation source, and a detector for temporally and spectrally resolved detection of the inherent fluorescence intensity of the respective previously exposed cell tissue is connected to an electronic evaluation unit with which the different autocorrelation function C(t) can be determined from the determined intensity measurement values.
  • the electronic evaluation unit With the electronic evaluation unit, the fractal dimension D F can be calculated and this value of the fractal dimension D F can be compared with a tumor-specific threshold.
  • An endocapsule can thereby include all required components or only parts of these, as is explained in detail further below.
  • a time-consuming preparation of the cell tissue to be examined as it is required in a biopsy is omitted.
  • the physical stress of patients can thereby be reduced since the examination result is present in a markedly shorter amount of time.
  • a very good differentiation can be made between malignant and benign cell tissue.
  • FIG. 1 is a diagram of the intensity decay response given a constant wavelength of 421 nm, acquired with temporal resolution.
  • FIG. 2 is a diagram of the intensity decay response acquired with temporal resolution, created with the mean value of multiple wavelengths within a wavelength interval around the wavelength of 421 nm.
  • FIG. 3 shows the curve of the difference autocorrelation function over time during decay of the intensity.
  • FIGS. 4-10 respectively show devices or endocapsules of different embodiments in accordance with the presence invention.
  • FIGS. 1 through 3 are based on examinations that were conducted not in vivo but rather in vitro for reasons of simplification, and for reasons of reproducibility.
  • the cell tissue samples were laid in a groove that represented a receptacle of the cell tissue samples and directed electromagnetic radiation via an optical fiber to specific, predetermined positions of the cell tissue samples.
  • a nitrogen laser was used as a radiation source.
  • the electromagnetic radiation used for the inherent fluorescence excitation of the cell tissue had a wavelength of 337 nm.
  • the extracted cell samples were cooled to a temperature of 15° C. to slow necrosis and held at this temperature at least until the end of the examination.
  • the electromagnetic radiation emitted from the cell tissue as a result of the inherent fluorescence was directed via the same optical fiber to a spectrometer with which a detection in the wavelength interval from approximately 300 nm to approximately 600 nm was possible.
  • a characteristic wavelength of 421 nm has been selected at which increased intensities of the inherent fluorescence occurred.
  • the value of the fractal dimension D F can be determined with the defined difference autocorrelation function and the slope of a straight line with (t ⁇ t 0 ) 2H and given knowledge of the exponent H.
  • the determined value D F can be compared with a tumor-specific threshold for the respective examined position of the respective cell tissue sample. For the examined tumors, this threshold was between 1.31 and 1.32.
  • the examined cell tissue in the respective cell tissue sample is healthy cell tissue free of tumor cells, at least at the location of the sample at which the examination has been conducted.
  • the invention can also be implemented at gleast two elements that can be detectable with the spectrometer, which wavelengths have a larger interval from one another.
  • the temporal intensity decay response can be implemented at the wavelengths 370 nm and 430 nm, possibly also with a described mean value calculation.
  • a device with which an examination (of the stomach mucosa 1 , for example) can be made in the manner described above is either formed by an endocapsule 2 that includes all necessary mechanisms or comprises an endocapsule in which only a portion of the necessary mechanisms (but in all cases a radiation source) are included, wherein the remaining portion of the mechanisms are located outside of the endocapsule and outside of the patient body (see FIG. 4-10 ).
  • a magnet system 3 that serves for navigation of the endocapsule with the use of an external magnetic field is present in the inner space of an endoscopy 2 .
  • the endocapsule 2 includes a radiation source 4 , for instance in the form of a laser diode or an LED ( FIG. 4 ).
  • the housing 5 of the endocapsule 2 is penetrated by an opening or, respectively, a window 6 made of radiation-permeable material in the region of the radiation source 4 .
  • the window 6 is arranged at one end of the endocapsule 2 , for example.
  • a battery (not shown) can be present in the endocapsule 2 to supply power to the radiation source 4 .
  • the power supply can take place via a battery or other power source arranged outside of the body, which battery or other power source is connected via a connecting cable 7 with the radiation source 4 .
  • a detector 11 to detect the fluorescence radiation 8 of the cell tissue is present in the region of the window 8 .
  • the detector can be formed from one or more photodiodes as well as a lens and filter system (not shown), wherein the latter serves for spectral resolution of the inherent fluorescence.
  • a mini-spectrometer that already includes an optical system for spectral resolution can serve as a detector 11 .
  • the spectrometers CM10988MA and CM11009MA that are available from Hamamatsu Deutschland GmbH are suitable.
  • the detector 11 detects the inherent fluorescence intensity of the cell tissue spectrally and with temporal resolution and relays the corresponding data to an electronic evaluation unit 9 which is arranged within the endocapsule 2 , corresponding to FIGS. 4 and 5 .
  • the data calculated by the evaluation unit 9 which data allow a conclusion about the presence or non-presence of a tumor, are transmitted to a device present outside of the patient body either via a radio interface 10 present in the endocapsule 2 or with a signal line 13 (for example via the connecting cable 7 ).
  • the device comprises a monitor on which a color coding or numerical values for the tumor probability are presented.
  • the radiation source is formed by the light exit window 14 of an end of an optical waveguide 15 arranged within the endocapsule 2 .
  • the optical waveguide 15 is directed out of the patient body via a connecting cable 7 connected with the endocapsule 2 , wherein electromagnetic radiation is fed into the other end of the optical waveguide with the aid of an external radiation source 23 .
  • the electronic evaluation unit 9 is located outside of the endocapsule 2 and also outside of the patient body.
  • the raw data detected by the detector 11 are transmitted to the external evaluation unit 9 either via a radio interface 10 or via a signal line 16 .
  • the signal line 16 can run in a connecting cable 7 fixed to the endocapsule 2 , wherein this connecting cable 7 can include other additional supply lines, for instance for power supply of the radiation source 4 .
  • the radiation emission can also take place via the exit window 14 of an optical waveguide, as in the exemplary embodiment shown in FIG. 5 .
  • An additional structural simplification, and therefore also a shrinking of the endocapsule 2 is achieved if the detector 11 is also arranged outside of the patient body ( FIG. 7 ). Only an optical waveguide 17 that ends in the region of the window 6 is present in the endocapsule 2 , wherein the inherent fluorescence radiation arrives in the optical waveguide 17 via the face 18 of said optical waveguide 17 .
  • the radiation source 4 can be formed by a module and an LED or a laser diode, or by an optical waveguide 15 or by its light exit window 14 .
  • An additional simplification of the endocapsule 2 can take place in that an optical waveguide serving for excitation of the cell tissue and an optical waveguide serving to detect the inherent fluorescence are formed by a single optical waveguide 17 ′ ( FIG.
  • the optical waveguide 17 ′ as well as the additional aforementioned optical waveguide 15 and 17 can be formed by one or multiple optical fibers.
  • the optical waveguides are advantageously provided with a protective jacket (not shown) or travel within a connecting cable 7 fixed to the endocapsule 2 .
  • a laser light source 24 operating in the visible range can be present in this.
  • a measurement spot 25 is generated on the examined cell tissue with this laser light source 24 .
  • a camera 26 is present in the endocapsule 2 , such that the measurement spot is visible at the images of the examined tissue and its surroundings that are acquired with the camera and, for example, allows an orientation over the examined area.
  • the distance between the detector 11 and the surface of the examined cell tissue should not change significantly or, respectively, a change of the distance should be accordingly taken into account and corrected in the evaluation.
  • a distance measurement device described in DE 10 2006 014 857 A1 that—in addition to the laser light source 24 and the camera 26 —comprises an evaluation unit (not shown) that can be integrated into the evaluation unit 9 , for example.
  • the light beam generated by the laser light source generates a distance-independent light marker or, respectively, the measurement spot 25 on the cell tissue.
  • the shape and size of the measurement spot 25 that is transmitted out from the camera 26 is thereby analyzed by the evaluation unit (not shown) with the aid of an image processing software, and the respective distance of the endocapsule 2 or, respectively, of the detector 11 from the cell tissue is determined from the shape and/or size of the measurement spot 25 .
  • a distance varying during the measurement can thus be compensated accordingly by the evaluation unit 9 in the calculation of the fractal dimension D F .
  • the images acquired by the camera 26 are transmitted out via cable or via radio interface 10 .
  • a fixed distance of the detector 11 from the cell tissue can be achieved in that a fixing device 27 is present in the endocapsule 2 , with which fixing device 27 this endocapsule 2 can be anchored in the tissue of the gastrointestinal tract.
  • a fixing device 27 is described in DE 10 2005 032 290 A1. It comprises an anchor 28 that can be released via a driver device 29 and is connected with the endocapsule 2 via a thread 31 .
  • the anchor 28 for example, can be found of a material that dissolves after a certain time.
  • radiation source 4 and detector 11 are arranged so as to be spatially variable (for instance are pivotable) within the endocapsule 2 , as this is indicated by the double arrow 30 in FIG. 10 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Endoscopes (AREA)
US13/805,205 2010-06-23 2011-05-11 Method and device for detecting tumorous tissue in the gastrointestinal tract with the aid of an endocapsule Expired - Fee Related US9232885B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102010024732A DE102010024732A1 (de) 2010-06-23 2010-06-23 Verfahren und Vorrichtung zur Erkennung von tumorbehaftetem Gewebe im Gastrointestinaltrakt mit Hilfe einer Endokapsel
DE102010024732 2010-06-23
DE102010024732.4 2010-06-23
PCT/EP2011/057582 WO2011160892A1 (de) 2010-06-23 2011-05-11 Verfahren und vorrichtung zur erkennung von tumorbehaftetem gewebe im gastrointestinaltrakt mit hilfe einer endokapsel

Publications (2)

Publication Number Publication Date
US20130096438A1 US20130096438A1 (en) 2013-04-18
US9232885B2 true US9232885B2 (en) 2016-01-12

Family

ID=44119032

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/805,205 Expired - Fee Related US9232885B2 (en) 2010-06-23 2011-05-11 Method and device for detecting tumorous tissue in the gastrointestinal tract with the aid of an endocapsule

Country Status (4)

Country Link
US (1) US9232885B2 (zh)
CN (1) CN102946793B (zh)
DE (1) DE102010024732A1 (zh)
WO (1) WO2011160892A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2988659T3 (pl) * 2013-04-23 2023-01-02 University Of Maine System Board Of Trustees Ulepszone sposoby charakterystyki tkanki
WO2015086629A1 (de) * 2013-12-11 2015-06-18 Leoni Kabel Holding Gmbh Medizinische lasersonde
US11119035B2 (en) 2018-04-26 2021-09-14 Ppg Industries Ohio, Inc. Systems and methods for rapid coating composition determinations
US11874220B2 (en) 2018-04-26 2024-01-16 Ppg Industries Ohio, Inc. Formulation systems and methods employing target coating data results
US10871888B2 (en) * 2018-04-26 2020-12-22 Ppg Industries Ohio, Inc. Systems, methods, and interfaces for rapid coating generation
US10970879B2 (en) 2018-04-26 2021-04-06 Ppg Industries Ohio, Inc. Formulation systems and methods employing target coating data results

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562100A (en) 1988-12-21 1996-10-08 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US20020150285A1 (en) 2001-03-28 2002-10-17 Nelson Alan C. Optical projection imaging system and method for automatically detecting cells having nuclear and cytoplasmic densitometric features associated with disease
US20050192478A1 (en) 2004-02-27 2005-09-01 Williams James P. System and method for endoscopic optical constrast imaging using an endo-robot
WO2006001020A2 (en) 2004-06-28 2006-01-05 Given Imaging Ltd. Device, system, and method for in-vivo analysis
DE102005032290A1 (de) 2005-07-11 2007-01-18 Siemens Ag Endoskopiekapsel sowie Verfahren zur Diagnose und/oder Therapie mittles einer Endoskopiekapsel
DE102006014857A1 (de) 2006-03-30 2007-07-19 Siemens Ag Endoskopische Vorrichtung mit Lichtemissionseinheit zur Gewinnung einer Tiefeninformation von einem Aufnahmeobjekt
CN101234026A (zh) 2008-03-07 2008-08-06 李立 一种乳腺病变定量化影像评价系统及其应用方法
US7572284B2 (en) 2003-10-06 2009-08-11 Siemens Aktiengesellschaft Method for automated localization of lesions in the gastrointestinal tract for treatment using laser light from an endorobot
US20090270702A1 (en) 2005-01-21 2009-10-29 Haishan Zeng Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging
US20090312618A1 (en) 2006-03-30 2009-12-17 Arne Hengerer Endoscopic device with biochip sensor
EP2251675A1 (de) 2009-05-15 2010-11-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung von Tumorbehaftetem Zellgewebe
US20100292543A1 (en) 2007-10-30 2010-11-18 Tufts University Analysis of Endogenous Fluorescence Images to Extract Morphological/Organization Information About Living Samples
WO2010130254A1 (de) 2009-05-15 2010-11-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe
US8187166B2 (en) 2001-08-29 2012-05-29 Siemens Aktiengesellschaft Minimally invasive medical system employing a magnetically controlled endo-robot
US8417324B2 (en) 2001-03-01 2013-04-09 Trustees Of Dartmouth College Fluorescence lifetime spectrometer (FLS) and methods of detecting diseased tissue

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562100A (en) 1988-12-21 1996-10-08 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US8417324B2 (en) 2001-03-01 2013-04-09 Trustees Of Dartmouth College Fluorescence lifetime spectrometer (FLS) and methods of detecting diseased tissue
US20020150285A1 (en) 2001-03-28 2002-10-17 Nelson Alan C. Optical projection imaging system and method for automatically detecting cells having nuclear and cytoplasmic densitometric features associated with disease
US8187166B2 (en) 2001-08-29 2012-05-29 Siemens Aktiengesellschaft Minimally invasive medical system employing a magnetically controlled endo-robot
US7572284B2 (en) 2003-10-06 2009-08-11 Siemens Aktiengesellschaft Method for automated localization of lesions in the gastrointestinal tract for treatment using laser light from an endorobot
US20050192478A1 (en) 2004-02-27 2005-09-01 Williams James P. System and method for endoscopic optical constrast imaging using an endo-robot
WO2006001020A2 (en) 2004-06-28 2006-01-05 Given Imaging Ltd. Device, system, and method for in-vivo analysis
US20090270702A1 (en) 2005-01-21 2009-10-29 Haishan Zeng Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging
DE102005032290A1 (de) 2005-07-11 2007-01-18 Siemens Ag Endoskopiekapsel sowie Verfahren zur Diagnose und/oder Therapie mittles einer Endoskopiekapsel
US20090312618A1 (en) 2006-03-30 2009-12-17 Arne Hengerer Endoscopic device with biochip sensor
DE102006014857A1 (de) 2006-03-30 2007-07-19 Siemens Ag Endoskopische Vorrichtung mit Lichtemissionseinheit zur Gewinnung einer Tiefeninformation von einem Aufnahmeobjekt
US20100292543A1 (en) 2007-10-30 2010-11-18 Tufts University Analysis of Endogenous Fluorescence Images to Extract Morphological/Organization Information About Living Samples
CN101234026A (zh) 2008-03-07 2008-08-06 李立 一种乳腺病变定量化影像评价系统及其应用方法
EP2251675A1 (de) 2009-05-15 2010-11-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung von Tumorbehaftetem Zellgewebe
WO2010130254A1 (de) 2009-05-15 2010-11-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und vorrichtung zur erkennung von tumorbehaftetem lebendem zellgewebe
US20120252057A1 (en) 2009-05-15 2012-10-04 Juergen Schrelber Method and device for detecting tumorous living cell tissue
US8981317B2 (en) * 2009-05-15 2015-03-17 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method and device for detecting tumorous living cell tissue

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Endomikroskopie ermöglicht gezielte Biopsien", Ärzte Zeitung Verlags-GmbH, Ärzte Zeitung, Nov. 25, 2004.
"Fluoreszenzdiagnostik in der Gastroenterologie", http://www.qualimedic.de/autofluoreszenzendoskopie.html, Apr. 14, 2010.
"Optical Cancer Diagnostics by Cooperative Phenomena," Gerich et al., Joint Korean-German Symposium on Medical Diagnostics (Oct. 29, 2009).
Benda et al., "TCSPC upgrade of a confocal FCS microscope", Review of Scientific Instruments, vol. 76, No. 3, 2005, pp. 033106-1-033106-4.
Gerich et al: "Detection of Cancer-Cells in Prostate Tissue with Time-Resolved Fluorescence" Frauenhofer IZFP.
Mini-Spectrometers-Compact and low cost mini-spectrometers, Hamamatsu Photonics K.K., Solid State Division, www.hamamatsu.com Oct. 2009.
Petersen et al., "Quantitation of Membrane Receptor Distributions by Image Correlation Spectroscopy: Concept and Application", Biophysical Journal, vol. 65, Sep. 1993, pp. 1135-1146.
Petersen et al: Quantitation of membrane receptor distributions by image correlation spectroscopy: concept and application, Biophysical Journal, New York, US, US, Bd. 65, NR.3, Sep. 1, 1993, pp. 1135-1146.
Salomon et al. "The Feasibility of Prostate Cancer Detection by Triple Spectroscopy," European Urology, vol. 55 (2009) pp. 376-384.
Salomon et al., "Prostate cancer detection by laser induced autofluorescence and multicomponent spectroscopy", Proceedings of SPIE-The International Society for Optical Engineering-International Conference on Lasers, Applications, and Technologies 2007: Laser Technologies for Medicine 2007 SPIE US, vol. 6734.
Weiss et al., "Anomalous Protein Diffusion in Living Cells as Seen by Fluorescence Correlation Spectroscopy", Biophysical Journal, vol. 84, No. 6, 2003, pp. 4043-4052.

Also Published As

Publication number Publication date
DE102010024732A1 (de) 2011-12-29
WO2011160892A1 (de) 2011-12-29
CN102946793B (zh) 2015-08-19
CN102946793A (zh) 2013-02-27
US20130096438A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
US10488340B2 (en) Imaging a target fluorophore in a biological material in the presence of autofluorescence
US9232885B2 (en) Method and device for detecting tumorous tissue in the gastrointestinal tract with the aid of an endocapsule
US20170105623A1 (en) Intra-operative use of fluorescence spectroscopy and applications of same
KR100415850B1 (ko) 레이저유도된차등정규화된형광스펙트럼을이용한암진단장치
CN101489471B (zh) 利用检测微血管血液含量早期增大来识别异常组织的装置
US9763744B2 (en) Biopsy device with integrated optical spectroscopy guidance
US20080097198A1 (en) Lymph Node Detector
US5687730A (en) Apparatus for detecting the presence of abnormal tissue within a target tissue beneath the skin of a patient
JPS62247232A (ja) 蛍光測定装置
EP2347703B1 (en) Cancerous or pre-cancerous tissue visualization method and device
CN102665559A (zh) 用于可视化目标癌组织的激发、检测和投射系统
WO2015164774A1 (en) Fluorescence guided surgical systems and methods gated on ambient light
Schäfauer et al. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study
US8981317B2 (en) Method and device for detecting tumorous living cell tissue
JP2005319212A (ja) 蛍光内視鏡装置
US20190167116A1 (en) Optical redox imaging systems and methods
Kim et al. Phase‐sensitive fluorescence detector for parathyroid glands during thyroidectomy: a preliminary report
RU131184U1 (ru) Система для оптической диагностики опухолевой ткани
Kang et al. System for fluorescence diagnosis and photodynamic therapy of cervical disease
SEKINE et al. Potential Application of Raman Spectroscopy for Real-time Diagnosis and Classification of Colorectal Cancer
Popenda et al. Fluorescence lifetime measurements with all-fiber optical setup for non-invasive in-vivo diagnostics
Borisova et al. Fluorescence spectroscopy of gastrointestinal tumors using δ-ALA
JPH04339240A (ja) がん性組織と良性または正常組織とを識別する方法および設備
Richards-Kortum et al. Spectroscopic probe for in vivo measurement of raman signals
JP2002125913A (ja) 蛍光検出装置

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIEMENS AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEHRE, JENS;NANKE, RALFE;REEL/FRAME:029492/0610

Effective date: 20121016

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: SIEMENS HEALTHCARE GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIEMENS AKTIENGESELLSCHAFT;REEL/FRAME:040656/0054

Effective date: 20161104

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GERICH, CAROLA;OPITZ, JOERG;SCHREIBER, JUERGEN;SIGNING DATES FROM 20200211 TO 20200319;REEL/FRAME:054105/0892

CC Certificate of correction
FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20240112